NexImmune, Inc.
NEXIDelisted Sep 6, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001538210
NexImmune, Inc. was delisted on Sep 6, 2024; its insiders filed their last Form 4 on Jun 13, 2024; 13 institutions reported holding it in 13F filings for Q2 2024, worth $408.6K in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 13
- Q2 2024, +1 vs. previous quarter
- 13F value
- $408.6K
- Reported value at the end of Q2 2024
- Superinvestors holding
- 0
- At the end of Q2 2024
Superinvestors holding NEXI, Q2 2024
No superinvestor reported holding NEXI at the end of Q2 2024.
Latest insider trades
Open-market purchases and sales by NexImmune, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 13, 2024 (view filing)7:58 PM ET | Jun 11 | 2 days | Jones KristiPresident and CEO | PPurchaseSeries A Preferred Stock, par value $0.0001 per share | +1 | $0.01 | +$0.01 | New position1 after | |
| Nov 22, 2023 (view filing) | Nov 21-22 | 1 day | Roemer Alan S.Director | SSale | −7.83K | $2.05 | −$16.0K | −100.0%0 after | 2 lots |
| Mar 31, 2023 (view filing)4:56 PM ET | Mar 30 | 1 day | Barer Sol JDirector | PPurchase | +400.0K | $0.4103 | +$164.1K | +22.0%2.22M after | |
| Nov 17, 2022 (view filing)8:40 PM ET | Nov 16-17 | 1 day | Barer Sol JDirector | PPurchase | +200.0K | $0.4811 | +$96.2K | +13.0%1.74M after | 2 lots |
| Jun 7, 2022 (view filing) | Jun 3-7 | 4 days | Verstandig GrantDirector | PPurchase | +66.9K | $2.21 | +$148.1K | +6.8%1.05M after | 3 lots |
| Jun 2, 2022 (view filing) | May 31-Jun 2 | 2 days | Verstandig GrantDirector | PPurchase | +133.1K | $2.23 | +$297.5K | +16.3%950.5K after | 3 lots |
| Jun 2, 2022 (view filing) | May 31-Jun 2 | 2 days | Barer Sol JDirector | PPurchase | +100.0K | $2.26 | +$226.0K | +6.9%1.56M after | 3 lots |
| Mar 30, 2022 (view filing) | Mar 29 | 1 day | Jones KristiPresident and CEO | PPurchase | +10.0K | $3.74 | +$37.4K | +15.9%73.1K after | |
| Mar 28, 2022 (view filing) | Mar 24-28 | 4 days | Verstandig GrantDirector | PPurchase | +190.6K | $3.94 | +$750.3K | +26.7%905.5K after | 3 lots |
| Mar 24, 2022 (view filing) | Mar 23 | 1 day | Barer Sol JDirector | PPurchase | +10.0K | $2.67 | +$26.7K | +0.7%1.52M after |
Top 10 13F holders, Q2 2024
The largest institutional positions in NexImmune, Inc. at the end of Q2 2024; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Sabby Management, LLC | 49,904 | $137.7K | 1.83% | −9,947−16.6% | Reduced |
| Slate Path Capital LP | 36,999 | $102.1K | 0.00% | 00.0% | Unchanged |
| EPIQ Capital Group, LLC | 15,624 | $43.1K | 0.02% | 00.0% | Unchanged |
| The PNC Financial Services Group, Inc. | 12,640 | $34.9K | 0.00% | 00.0% | Unchanged |
| Vanguard Group Inc | 12,010 | $33.1K | 0.00% | 00.0% | Unchanged |
| Raymond James & Associates | 10,804 | $29.8K | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 4,000 | $11.1K | 0.00% | +4,000 | New |
| Comerica Bank | 3,256 | $8.99K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 2,121 | $5.85K | 0.00% | +541+34.2% | Added |
| UBS Group AG | 638 | $1.76K | 0.00% | +637+63,700.0% | Added |